NB Capital was seeded in 2001 by a small group of highly experienced biotech investors and a pharmaceutical company. Since the beginning we have been focused on investing capital in public and private equity markets using principles of risk aversion and innovation.

Our current investor base is globally spread institutional, SWFs and family offices. Discretionary capital approximates 1 billion USD. Focus has been on all phases of pharmaceutical drug development and commercial enterprise, a sector with an annual revenue of more than one trillion USD globally. Almost every institutional investor is exposed to this sector, yet it remains one of the most complex, treacherous and yet rewarding sectors of them all. With more than 25 years of investment experience, our Chief Executive Officer and a multifaceted expert team aim at finding the rare opportunities that add value to even the largest and most specialized investors.

NB Capital is focused on providing value add investments to even the largest institutional investor with internal healthcare capabilities. Much asset management today is disguised and leveraged high-cost beta. We are committed to providing clear-cut documented value add and nothing else. We have developed a methodology to systematically capitalize the global information and data overload, biased incentives and irrationalities in the complex biopharma area. The methodology has been refined over 25 years in the biopharmaceutical area, from seed to 150 bln. USD market cap companies in this huge market cap sector.

The aim is to find truly low risk investments (defined as low risk of losing capital) with a potential upside to be captured over a 2-3 year time frame, all tailored to the investors risk-tolerance. This approach has been validated with multi-year performance in the context of very large investors with existing beta-exposure in global equities.